Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (SNOA) on March 21, 2025. The report discloses the entry into a material definitive agreement amendment regarding the company's Microcyn technology-based products.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a contractual agreement rather than periodic financial performance data.
Material Changes
- Amendment to Supply Agreement: On March 21, 2025, the company entered into Amendment No. 1 to a Master Supply Agreement previously executed on January 29, 2025, with WellSpring Pharmaceutical Corporation.
- Scope Expansion: The amendment facilitates the sale of additional Microcyn technology-based products to large retailers in the United States.
- Contract Terms: The underlying Master Supply Agreement has an initial term of two years, subject to three automatic one-year renewal periods.
Outlook, Risks, and Management Commentary
The filing contains forward-looking statements regarding the company's intentions and expectations related to the agreement. Management notes that actual outcomes may differ materially due to risks and uncertainties discussed in the company's Annual Report on Form 10-K. The company does not undertake an obligation to update these statements except as required by law.
Investor Verification Checklist
- Review the full text of Amendment No. 1 (Exhibit 10.1) for specific product details and commercial terms omitted from this summary.
- Verify the financial impact of the expanded product scope in future quarterly reports.
- Confirm the status of the initial Master Supply Agreement filed on January 30, 2025.
- Assess the strategic importance of the WellSpring partnership for the company's retail distribution strategy.